Alpha 2.0
Login Register
» Authors » Richard Sparks

Richard Sparks

Explore the profile of Richard Sparks including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 316
Followers 0
Related Specialties
Nuclear Medicine
Chemistry
Oncology
Top 10 Co-Authors
Andrew P Combs
Joel Lazewatsky
Paul Crane
Yanlong Li
Padmaja Polam
Brian Glass
Timothy C Burn
Richard Wynn
Magnus Dahlbom
Michael Bower
Published In
J Nucl Med
Int J STD AIDS
J Med Chem
Clin Cancer Res
Eur J Nucl Med Mol Imaging
Affiliations
Soon will be listed here.
Recent Articles
1.
Initial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
Hansen A, Probst S, Beauregard J, Viglianti B, Michalski J, Tagawa S, et al.
Front Oncol . 2025 Jan; 14():1483953. PMID: 39839782
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase...
2.
Renal and Multiorgan Safety of Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause B, et al.
J Nucl Med . 2023 Dec; 65(1):71-78. PMID: 38050121
In the VISION trial, [Lu]Lu-PSMA-617 (Lu-PSMA-617) plus protocol-permitted standard of care significantly improved overall survival and radiographic progression-free survival compared with standard of care alone in patients with prostate-specific membrane...
3.
Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging
Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, et al.
J Nucl Cardiol . 2018 Nov; 26(6):2018-2030. PMID: 30488323
Methods: 12 normal subjects were injected with 58.5 to 121 MBq (1.58 to 3.27 mCi) of Flurpiridaz intravenously at rest on Day 1 and 57 to 171 MBq (1.54 to...
4.
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Stubbs M, Burn T, Sparks R, Maduskuie T, Diamond S, Rupar M, et al.
Clin Cancer Res . 2018 Sep; 25(1):300-311. PMID: 30206163
Purpose: Bromodomain and extraterminal domain (BET) proteins regulate the expression of many cancer-associated genes and pathways; BET inhibitors have demonstrated activity in diverse models of hematologic and solid tumors. We...
5.
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
Yue E, Sparks R, Polam P, Modi D, Douty B, Wayland B, et al.
ACS Med Chem Lett . 2017 May; 8(5):486-491. PMID: 28523098
A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor , INCB24360 (epacadostat). The molecular structure of INCB24360 contains several previously unknown or underutilized...
6.
A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of 99mTc-Sestamibi in Pediatric Subjects
Azarbar S, Salardini A, Dahdah N, Lazewatsky J, Sparks R, Portman M, et al.
J Nucl Med . 2015 Apr; 56(5):728-36. PMID: 25858045
Unlabelled: Myocardial perfusion imaging has long been used off label by practitioners attending for children with cardiac aliments. To provide clinicians with evidence-based dosage recommendation, a phase I-II, open-label, nonrandomized,...
7.
Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation
Sinusas A, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu Y, et al.
J Nucl Med . 2014 Jul; 55(9):1445-51. PMID: 24994931
Unlabelled: A novel (18)F-labeled ligand for the norepinephrine transporter (N-[3-bromo-4-(3-(18)F-fluoro-propoxy)-benzyl]-guanidine [LMI1195]) is in clinical development for mapping cardiac nerve terminals in vivo using PET. Human safety, whole-organ biodistribution, and radiation...
8.
Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest
Maddahi J, Czernin J, Lazewatsky J, Huang S, Dahlbom M, Schelbert H, et al.
J Nucl Med . 2011 Aug; 52(9):1490-8. PMID: 21849402
Unlabelled: (18)F-labeled BMS747158 is a novel myocardial perfusion imaging tracer that targets mitochondrial complex 1. The objectives of this phase I study were to evaluate radiation dosimetry, biodistribution, human safety,...
9.
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study
Takano A, Gulyas B, Varrone A, Karlsson P, Sjoholm N, Larsson S, et al.
Eur J Nucl Med Mol Imaging . 2011 Jul; 38(11):2058-65. PMID: 21732107
Purpose: [(18)F]FEDAA1106 is a recently developed positron emission tomography (PET) radioligand for in vivo quantification of the 18 kDa translocator protein [TSPO or, as earlier called, the peripheral benzodiazepine receptor...
10.
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics
Combs A, Yue E, Bower M, Ala P, Wayland B, Douty B, et al.
J Med Chem . 2005 Oct; 48(21):6544-8. PMID: 16220970
Structure-based design led to the discovery of novel (S)-isothiazolidinone ((S)-IZD) heterocyclic phosphotyrosine (pTyr) mimetics that when incorporated into dipeptides are exceptionally potent, competitive, and reversible inhibitors of protein tyrosine phosphatase...